The 40 references in paper S. Avdeev N., С. Авдеев Н. (2017) “Новые возможности терапии идиопатического легочного фиброза // New abilities in therapy of idiopathic pulmonary fibrosis” / spz:neicon:pulmonology:y:2017:i:4:p:502-514

1
Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.Am. J. Respir. Crit. Care Med. 2011; 183 (3): 788–824. DOI: 10.1164/rccm.2009-040GL.
(check this in PDF content)
2
Raghu G., Chen S.Y., Yeh W.S. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir. Med. 2014; 2 (7): 566–572. DOI: 10.1016/S22132600(14)70101-8.
(check this in PDF content)
3
Manen M.J., Birring S.S., Vancheri C. et al. Cough in idiopathic pulmonary fibrosis. Eur. Respir. Rev.2016; 25 (141): 278–286. DOI: 10.1183/16000617.0090-2015.
(check this in PDF content)
4
Yount S.E., Beaumont J.L., Chen S.Y. et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung. 2016; 194 (2): 227–234. DOI: 10.1007/s00408-0169850-y
(check this in PDF content)
5
Ley B., Collard H.R., King T.E. Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2011; 183 (4): 431–440. DOI: 10.1164/rccm.201006-0894CI.
(check this in PDF content)
6
Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am. J. Respir. Crit. Care Med. 2016; 194 (3): 265–275. DOI: 10.1164/rccm.201604-0801CI.
(check this in PDF content)
7
Cottin V. The impact of emphysema in pulmonary fibrosis. Eur. Respir. Rev. 2013; 22 (128): 153–157. DOI: 10.1183/ 09059180.00000813.
(check this in PDF content)
8
Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46 (1): 186–196. DOI: 10.1183/09031936.00217614.
(check this in PDF content)
9
Raghu G., Amatto V.C., Behr J. et al. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur. Respir. J. 2015; 46 (4): 1113–1130. DOI:
(check this in PDF content)
10
1183/13993003.02316-2014. 10. Bonella F., Kreuter M., Hagmeyer L. et al. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration. 2016; 92 (2): 98–106. DOI: 10.1159/000448288.
(check this in PDF content)
11
Maher R.L., Hanlon J., Hajjar E.R. Clinical consequences of polypharmacy in elderly.Exp. Opin. Drug Saf.2014; 13 (1): 57–65. DOI: 10.1517/14740338.2013.827660.
(check this in PDF content)
12
Vancheri C., Cottin V., Kreuter M. et al. IPF, comorbidities and management implications. Sarcoidos. Vasc. Diffuse Lung Dis. 2015; 32 (Suppl. 1): 17?23.
(check this in PDF content)
13
Demedts M., Behr J., Buhl R. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353 (21): 2229–2242. DOI: 10.1056/NEJMoa 042976.
(check this in PDF content)
14
Raghu G., Anstrom K.J., King T.E. Jr et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med.2012; 366 (21): 1968–1977. DOI: 10. 1056/NEJMoa1113354.
(check this in PDF content)
15
Raghu G., Brown K.K., Costabel U. et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2008; 178 (9): 948–955. DOI: 10.1164/rccm.2007091446OC.
(check this in PDF content)
16
King T.E. Jr, Albera C., Bradford W.Z. et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009; 374 (9685): 222– 228. DOI: 10.1016/S0140-6736(09)60551-1.
(check this in PDF content)
17
Daniels C.E., Lasky J.A., Limper A.H. et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 2010; 181 (6): 604–610. DOI: 10.1164/rccm.2009060964OC.
(check this in PDF content)
18
Noth I., Anstrom K.J., Calvert S.B. et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.Am. J. Respir. Crit. Care Med. 2012; 186 (1): 88–95. DOI: 10.1164/rccm.201202-0314OC.
(check this in PDF content)
19
King T.E. Jr, Behr J., Brown K.K. et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.Am. J. Respir. Crit. Care Med. 2008; 177 (1): 75–81. DOI: 10.1164/rccm.200705-732OC.
(check this in PDF content)
20
King T.E. Jr, Brown K.K., Raghu G. et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.Am. J. Respir. Crit. Care Med.2011; 184 (1): 92–99. DOI: 10.1164/rccm.201011-1874OC.
(check this in PDF content)
21
Raghu G., Million-Rousseau R., Morganti A. et al. Macitentan for the reatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur. Respir. J. 2013; 42 (6): 1622–1632. DOI: 10.1183/09031936.00104612.
(check this in PDF content)
22
Raghu G., Behr J., Brown K.K. et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.Ann. Intern. Med. 2013; 158 (9): 641–649. DOI: 10.7326/0003-4819-158-9-201305070-00003.
(check this in PDF content)
23
Martinez F.J., de Andrade J.A., Anstrom K.J. et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.N. Engl. J. Med. 2014; 370 (22): 2093–2101. DOI: 10.1056/NEJMoa1401739.
(check this in PDF content)
24
Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. 512Пульмонология. 2017; 27 (4): 502–514. DOI: 10.18093/08693018932017327343502–514 N. Engl. J. Med. 2011; 365 (12): 1079–1087. DOI: 10. 1056/NEJMoa1103690. 41. Yu Z.H., Wang D.D., Zhou Z.Y. et al. Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice. Biol. Pharm. Bull.2012; 35 (5): 731–736. 42. Chen Y., Zhao M., Fu M. et al. The role of calcineurin in the lung fibroblasts proliferation and collagen synthesis induced by basic fibroblast growth factor. Chin. Med. J. (Engl.) 2003; 116 (6): 857–862. 43. Inoue Y., King T.E. Jr, Tinkle S.S
(check this in PDF content)
25
Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2071–2082. DOI: 10.1056/NEJMoa1402584.
(check this in PDF content)
26
Raghu G., Rochwerg B., Zhang Y. et al. An official ATS/ ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline.Am. J. Respir. Crit. Care Med.2015; 192 (2): e3–e19. DOI: 10.1164/rccm.201506-1063ST.
(check this in PDF content)
27
King T.E., Pardo A., Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011; 378 (9807): 1949–1961. DOI: 10. 1016/S0140-6736(11)60052-4.
(check this in PDF content)
28
Ahluwalia N., Shea B.S., Tager A.M. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.Am. J. Respir. Crit. Care Med. 2014; 190 (8): 867–878. DOI: 10.1164/rccm.2014030509PP.
(check this in PDF content)
29
Selman M., King T.E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001; 134 (2): 136–151.
(check this in PDF content)
30
Borensztajn K., Crestani B., Kolb M. Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers – insights from the bench side. Respiration. 2013; 86 (6): 441–452. DOI: 10.1159/000357598.
(check this in PDF content)
31
Günther A., Korfei M., Mahavadi P. et al. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis.Eur. Respir. Rev. 2012; 21 (124): 152–160. DOI: 10. 1183/09059180.00001012.
(check this in PDF content)
32
Noble P.W., Barkauskas C.E., Jiang D. Pulmonary fibrosis: patterns and perpetrators. J. Clin. Invest. 2012; 122 (8): 2756–2762. DOI: 10.1172/JCI60323.
(check this in PDF content)
33
Selman M., Pardo A. Revealing the pathogenic and agingrelated mechanisms of the enigmatic idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2014; 189 (10): 1161–1172. DOI: 10.1164/rccm.201312-2221PP.
(check this in PDF content)
34
Wuyts W.A., Agostini C., Antoniou K.M. et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur. Respir. J. 2013; 41 (5): 1207–1218. DOI: 10.1183/09031936.00073012.
(check this in PDF content)
35
Fukihara J., Kondoh Y. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.Exp. Rev. Respir. Med.2016; 10 (12): 1247–1254. DOI: 10.1080/17476348. 2016.1249854.
(check this in PDF content)
36
Clark J.G., Madtes D.K., Raghu G. Effects of plateletderived growth factor isoforms on human lung fibroblast proliferation and procollagen gene expression. Exp. Lung Res.1993; 19 (3): 327–344.
(check this in PDF content)
37
Bonner J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev.2004; 15 (4): 255–273. DOI: 10.1016/j.cytogfr.2004.03.006.
(check this in PDF content)
38
Martinet Y., Rom W.N., Grotendorst G.R. et al. Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 1987; 317 (4): 202–209. DOI: 10.1056/NEJM198707233170404.
(check this in PDF content)
39
Adamali H.I., Maher T.M. Current and novel drug therapies for idiopathic pulmonary fibrosis.Drug Des. Devel. Ther. 2012; 6: 261–272. DOI: 10.2147/DDDT.S29928.
(check this in PDF content)
40
Xiao L., Du Y., Shen Y. et al. TGF-β1 induced fibroblast proliferation is mediated by the FGF-2/ERK pathway. Front. Biosci.(Landmark Ed). 2012; 17: 2667–2674. http://journal.pulmonology.ru/pulm513 58. Tandon K., Herrmann F.E., Ayaub E. et al. Nintedanib
(check this in PDF content)